阿巴西普与阿达木单抗在共享表位阳性与阴性类风湿关节炎患者中的比较有效性
基于英国53个中心的前瞻性观察队列,342例启动阿巴西普或阿达木单抗的类风湿关节炎患者纳入分析,整合人口学、临床与药理学变量的多变量模型显示两药疗效无差异,Val11与EULAR反应存在弱独立关联(P=0.02)但两药间该效应无显著差异,未发现HLA分型有助于支持这两种药物的处方决策。
要点
- 阿巴西普与阿达木单抗在类风湿关节炎患者中的疗效无差异。
- Val11与EULAR反应存在弱独立关联(P=0.02),但两药间该效应无显著差异。
- 未发现HLA分型对这些药物的处方决策具有临床实用价值的证据。
核心结论
- 未发现HLA分型有助于支持阿巴西普或阿达木单抗处方决策的证据。
研究设计与样本
- 类风湿关节炎遗传学与基因组学研究联盟为全国性观察队列,从英国53个中心招募启动生物制剂治疗前的患者并前瞻性随访12个月。
- 342例启动阿巴西普或阿达木单抗的患者符合本分析条件,并在多个时间点测定阿巴西普、阿达木单抗与甲氨蝶呤的血清药物水平。
- 采用整合人口学、临床与药理学变量的多变量模型检验共享表位或Val11拷贝数与治疗反应(EULAR反应、DAS28缓解、DAS28变化)的关联,并通过交互项显著性评估药物与遗传标志物间的差异有效性。
主要发现
- 阿巴西普与阿达木单抗的疗效无差异。
- 遗传标志物与治疗反应存在弱独立关联证据(Val11与EULAR反应:P=0.02),但两药间该效应无显著差异。
临床怎么用
- 作者结论为未发现HLA分型对支持这两种药物的处方决策具有临床实用性的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The effect of the shared epitope (SE) and valine at position 11 (Val11) of HLA-DRB1 on the activation of CD4+ T cells is expected to be diminished by abatacept, a costimulation blocker. However, published evidence on the value of genetic stratification for abatacept treatment is conflicting. We aimed to compare the difference in effectiveness of abatacept and adalimumab in patients carrying the SE (or Val11). METHODS: The Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate is a nationwide observational cohort study recruiting patients from 53 centers across the United Kingdom before the initiation of biologic treatment and following them up prospectively for 12 months. Three hundred forty-two patients starting either abatacept or adalimumab were eligible for this analysis. Serum drug levels for abatacept, adalimumab, and methotrexate were determined at multiple time points. Multivariate modeling integrating demographic, clinical, and pharmacological variables was used to test for associations between the number of copies of the SE or Val11 and response to treatment (EULAR response; Disease Activity Score in 28 joints [DAS28] remission; change in DAS28). Differential effectiveness between drugs and genetic markers was assessed by the significance of their interaction term. RESULTS: There was no difference in the efficacy of abatacept versus adalimumab. We found weak evidence for an independent association of genetic markers with response to treatment (Val11 with EULAR response: P = 0.02), but there was no significant difference in this effect between drugs. CONCLUSION: We found no evidence that HLA typing is clinically useful to support prescription decisions for these two drugs.
引用
- Yap CF, Nair N, Sharma SD, et al. Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2025. PMID: 40567118. doi:10.1002/art.43298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。